Eradication of Helicobacter pylori: Recent advances in treatment

Fundamental and Clinical Pharmacology

Volumn 19, Issue 4, 2005, Pages 421-427

  McLoughlin, Ramona M ^a   O'Morain, Colm A ^a   O'Connor, Humphrey J ^a  

^a NONE

Author keywords

Eradication; H. pylori

Indexed keywords

AMOXICILLIN; BISMUTH SALT; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; IMIDAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BONE MARROW TOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LEUKOPENIA; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH TUMOR; TASTE DISORDER; TASTE PERVASION; THROMBOCYTOPENIA; TREATMENT FAILURE;

DRUG RESISTANCE, BACTERIAL; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PATIENT COMPLIANCE; RIFABUTIN; TIME FACTORS; TREATMENT FAILURE;

EID: 22344442652     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00340.x     Document Type: Review

References (51)

1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 1 1311-1315.
2. Hentschel E., Brandstatter G., Dragosics B. et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N. Engl. J. Med. (1993) 328 308-312.
3. Sung J.J., Chung S.C., Ling T.K. et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N. Engl. J. Med. (1995) 332 139-142.
4. Fischbach W., Goebeler-Kolve, M.E., Dragosics B. et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut (2004) 53 34-37.
5. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut (2001) 49 347-353.
6. Uemura N., Okamoto S., Yamamoto S. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345 784-789.
7. Ito M., Haruma K., Kamada T. et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment. Pharmacol. Ther. (2002) 16 1449-1456.
8. Malfertheiner P., Megraud F., O'Morain C. et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. (2002) 16 167-180.
9. Delaney B.C., Innes M.A., Deeks J. et al. Initial management strategies for dyspepsia (Cochrane Review), in: The Cochrane Library, Issue 4. Update Software, Oxford, 2002.
10. Zullo A., Hassan C., Lorenzetti R. et al. Helicobacter pylori eradication: do we have another ace up our sleeve? Dig. Liver Dis. (2001) 33 805-806.
11. Gomollon F., Ducons F.A., Ferrero M. et al. Quadruple therapy is effective for eradication of Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter (1999) 4 222-225.
12. Janssen M.J.R., Van Oijen A.H.A.M., Verbeek A.L.M. et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment. Pharmacol. Ther. (2001) 15 613-624.
13. Vergara M., Vallve M., Gisbert J.P., Calvet X. Meta-analysis: comparative efficacy of different proton pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2003) 18 647-654.
14. Huang J.Q., Hunt R.H. Treatment after failure: the problem of 'non-responders'. Gut (1999) 45 (Suppl 1) 140-144.
15. Broutet N., Tchamgoue S., Pereira E. et al. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. (2003) 17 99-109.
16. Huang J.Q., Hunt R.H. Are one-week anti-H. pylori treatments more effective in patients with peptic ulcer disease (PUD) than in those with non-ulcer dyspepsia (NUD)? A meta-analysis. Am. J. Gastroenterol. (1998) 93 1639-1643.
17. Hiyama T., Tanaka S., Masuda H. et al. Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J. Gastroenterol. Hepatol. (2003) 18 1202-1207.
18. Crone J., Granditsch G., Huber W.D. et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J. Pediatr. Gastroenterol. Nutr. (2003) 36 368-371.
19. McMahon B.J., Hennessy T.W., Bensler J.M. et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. (2003) 139 463-469.
20. Wolle K., Leodolter A., Malfertheiner P. et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995-2000. J. Med. Microbiol. (2002) 51 705-709.
21. Koivisto T.T., Rautelin H.I., Voutilainen M.E. et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment. Pharmacol. Ther. (2004) 19 1009-1017.
22. Bronzwaer S.L., Cars O., Buchholz U. et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. (2002) 8 278-282.
23. Houben M.H., van de Beek D., Hensen E.F. et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. (1999) 13 1047-1055.
24. Murakami K., Sato R., Okimoto T. et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. (2003) 17 119-123.
25. Neri M., Milano A., Laterza F. et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment. Pharmacol. Ther. (2003) 18 821-827.
26. Romano M., Marmo R., Cuomo A. et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. (2003) 1 273-278.
27. Zullo A., Hassan C., Lorenzetti R. et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori. Dig. Liver Dis. (2003) 35 357-361.
28. Calvet X., Garcia N., Lopez T. et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14 603-609.
29. Gene E., Calvet X., Azagra R., Gisbert J.P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. (2003) 17 1137-1143.
30. Gene E., Calvet X., Azagra R. et al. Triple vs. Quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol. Ther. (2003) 18 543.
31. O'Morain C., Borody T., Parley A. et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther. (2003) 17 415-420.
32. Zullo A., Vaira D., Vakil N. et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther. (2003) 17 719-726.
33. Hassan C., De Francesco V., Zullo A. et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment. Pharmacol. Ther. (2003) 18 641-646.
34. De Francesco V., Delia Valle N., Stoppino V. et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment. Pharmacol. Ther. (2004) 19 993-998.
35. De Francesco V., Zullo A., Margiotta M. et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment. Pharmacol. Ther. (2004) 19 407-414.
36. Hojo M., Miwa H., Nagahara A. et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. (2001) 7 690-700.
37. Lamouliatte H., Megraud F., Delchier J.C. et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther. (2003) 18 791-797.
38. Gisbert J.P., Calvet X., Bujanda L. et al. Rescue therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter (2003) 8 90-94.
39. Perri F., Festa V., Clemente R. et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. (2001) 96 58-62.
40. Wong W.M., Gu Q., Lam K. et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17 553-560.
41. Qasim A., Sebastian S., Thornton O. et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment. Pharmacol. Ther. (2005) 21 91-96.
42. Canducci F., Ojetti V., Pola P., et al. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment. Pharmacol. Ther. (2001) 15 143.
43. Di Caro S., Assunta Zocco M., Cremonini F. et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. (2002) 14 1309-1312.
44. Cammarota G., Cianci R., Cannizzaro O. et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14 1339-1343.
45. Watanabe Y., Aoyama N., Shirasaka D. et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig. Liver Dis. (2003) 35 711-715.
46. Perri F., Festa V., Merla A. et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment. Pharmacol. Ther. (2003) 18 815-820.
47. Zullo A., Hassan C., De Francesco V. et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver Dis. (2003) 35 232-236.
48. Nista E.C., Candelli M., Cremonini F. et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment. Pharmacol. Ther. (2003) 18 627-633.
49. Fakheri H., Malekzadeh R., Merat S. et al. Clarithromycin versus furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment. Pharmacol. Ther. (2001) 15 411-416.
50. Fakheri H., Merat S., Malekzadeh R. et al. Low dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2004) 19 89-93.
51. Roghani H.S., Massarrat S., Shirekhoda M., Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J. Gastroenterol. Hepatol. (2003) 18 778-782.